

Supplementary Table S5. References for case-reports and case-series concerning nonsteroidal anti-inflammatory drugs (NSAIDs), non-biologic and biologic drugs used to treat rheumatic diseases, SLR-period 2008– 2015<sup>1</sup>.

Drug	Type of publication in numbers	References on Case-reports/case-series
Non selective COX-inhibitors (classical NSAIDs)	<b>3 Cohorts</b> 3 Case-controls	-----
Selective COX – II Inhibitors (rofecoxib, celecoxib, etoricoxib)	3 Case-controls	-----
Glucocorticoids (any route/formulation)	<b>2 Cohorts</b> 5 Case-controls 17 Case-reports/series (1 abstract)	[1-17]
Antimalarials	<b>2 Cohorts</b> 4 Case-controls	-----
Sulfasalazine	<b>2 Cohorts</b> 2 Case-controls	-----
Leflunomide	<b>2 Cohorts</b> (1 abstract) 1 Case-control 4 Case-reports/series	[18-21]
Azathioprine	<b>4 Cohorts</b> (1 abstract) 7 Case-controls 7 Case-reports/series (1 abstract)	[22-28]
Methotrexate	<b>2 Cohorts</b> 2 Case-controls 8 Case-reports/series	[29-36]
Cyclo phosphamide	<b>2 Cohorts</b> 28 Case-reports/series (2 abstracts)	[37-64]
Ciclosporin	<b>2 Cohorts</b> 1 case-control 11 Case-reports/series (1 abstract)	[28 ,65-74]
Tacrolimus	<b>1 Cohort</b> 1 Case-control 10 Case-reports/series	[5 ,69 ,75-82]
Mycophenolate mofetil	<b>2 Cohorts</b> 1 Register data 20 Case-reports/series (2 abstracts)	[66 ,83-101]
Colchicine	<b>1 Cohort</b> 1 Case-control 1 Case-series	[102]
IVIg	<b>3 Cohorts</b> 3 Case-reports/series	[103-105]
Tofacitinib	1 Case-series (abstract)	[106]
Infliximab	<b>9 Cohorts</b> (1 abstract) 4 Case-controls (1 abstract) 2 Register data (1 abstract) 16 Case-reports/series (3 abstracts)	[107-123]
Adalimumab	<b>10 Cohorts</b> (2 abstracts) 5 Case-controls (1 abstract) 2 Register data (1 abstract) 6 Case-reports/series	[111 ,118 ,121 ,124-127]

	(1 abstract)	
<b>Etanercept</b>	<b>3 Cohorts</b> 3 Case-controls (1 abstract) 2 Register data (1 abstract) 11 Case-reports/series (3 abstracts)	[111 ,117 ,118 ,121 ,128-135]
<b>Certolizumab</b>	<b>2 Cohorts</b> 1 Case-control 2 Case-reports/series	[136 ,137]
<b>Golimumab</b>	<b>1 Cohort</b> 1 Case-series (abstract)	[138]
<b>All TNF-inhibitors, including studies not differentiating between them</b>	<b>10 Cohorts (3 abstracts)</b> 5 Case-controls (1 abstract) 2 Register data (1 abstract) 32 Case-reports/series (7 abstracts)	[107-135 ,137- 139]
<b>Rituximab</b>	1 Register data 20 Case-reports/series	[60 ,140-158]
<b>Anakinra</b>	1 Register data 3 Case-reports	[159-161]
<b>Abatacept</b>	1 Case- series <sup>8</sup> 1 Case-report	[150 ,162]
<b>Tocilizumab</b>	1 Register-data 2 Case-series (2 abstracts)	[163 ,164]
<b>Ustekinumab</b>	1 Register data 4 Case-reports/series (1 abstract)	[165-168]
<b>Belimumab</b>	1 Register data 1 case-series (abstract)	[169]

## REFERENCES

1. Abou-Nassar, K, Karsh, J, Giulivi, A, *et al.* Successful prevention of thrombotic thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma exchanges throughout pregnancy in a patient with systemic lupus erythematosus and a prior history of refractory TTP and recurrent fetal loss. *Transfus Apher Sci* 2010;43:29-31.
2. Adler, S, Lahmer, T, Heemann, UWE, *et al.* Combined Takayasu arteritis and Hashimoto thyroiditis during 3 consecutive pregnancies. *J Rheumatol* 2009;36:1555-56.
3. Alfhaily, F, Watts, R, Leather, A. Wegener's granulomatosis occurring de novo during pregnancy. *Clin Exp Rheumatol* 2009;27:S86-S88.
4. Ali, HS. Pemphigus vulgaris during pregnancy - A case report. *Journal of Pakistan Association of Dermatologists* 2011;21:301-03.
5. Alsuwaida, A. Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. *Mod Rheumatol* 2011;21:73-75.
6. Asgari, N, Henriksen, TB, Petersen, T, *et al.* Pregnancy outcomes in a woman with neuromyelitis optica. *Neurology* 2014;83:1576-7.
7. de Moraes e Silva, FA, Bonassi, M, Steiner, D, *et al.* Rosacea fulminans in pregnancy with ocular perforation. *J Dtsch Dermatol Ges* 2011;9:542-3.
8. Homar, V, Grosek, S, Battelino, T. High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. *Neonatology* 2008;94:306-9.

9. Huang, YH, Chen, YP, Liang, CC, *et al.* Impetigo herpetiformis with gestational hypertension: a case report and literature review. *Dermatology* 2011;222:221-4.
10. Khandelwal, M, Lal, N, Fischer, RL, *et al.* Takayasu arteritis and pregnancy case report and review of the literature. *Obstet Gynecol Surv* 2009;64:258-72.
11. Kurtoglu, S, Sarici, D, Akin, MA, *et al.* Fetal adrenal suppression due to maternal corticosteroid use: case report. *J Clin Res Pediatr Endocrinol* 2011;3:160-2.
12. Luan, L, Han, S, Zhang, Z, *et al.* Personal treatment experience for severe generalized pustular psoriasis of pregnancy: two case reports. *Dermatol Ther* 2014;27:174-7.
13. Sebestyen, A, Varbiro, S, Sara, L, *et al.* Successful management of pregnancy with nephrotic syndrome due to preexisting membranous glomerulonephritis: a case report. *Fetal Diagn Ther* 2008;24:186-9.
14. Streit, M, Speich, R, Fischler, M, *et al.* Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. *J Med Case Rep* 2009;3:7255.
15. Tien, MC, Teoh, SC. Treatment of Vogt-Koyanagi-Harada syndrome in pregnancy. *Can J Ophthalmol* 2009;44:211-2.
16. Yamamoto, M, Tabeya, T, Suzuki, C, *et al.* Adult-onset Still's disease in pregnancy. *Mod Rheumatol* 2012;22:163-65.
17. Yeeles, H, Sanderson, P, Shepherd, D, *et al.* The complexities of neuromyelitis optica and pregnancy: A case report and review of the literature. [abstract]. *BJOG* 2013;120(Suppl):101-2.
18. Cassina, M, Johnson, DL, Robinson, LK, *et al.* Pregnancy outcome in women exposed to leflunomide before or during pregnancy. *Arthritis Rheum* 2012;64:2085-94.
19. Hajdyla-Banas, I, Banas, T, Rydz-Stryszowska, I, *et al.* Pregnancy course and neonatal outcome after exposure to leflunomide--2 cases report and review of literature. *Przegl Lek* 2009;66:1069-71.
20. Heine, K, Poets, CF. A pair of twins born after maternal exposure to leflunomide. *J Perinatol* 2008;28:841-42.
21. Kraemer, B, Abele, H, Hahn, M, *et al.* A successful pregnancy in a patient with Takayasu's arteritis. *Hypertens Pregnancy* 2008;27:247-52.
22. Basak, S. Obstetric outcome in idiopathic necrotising myopathy with anti signal recognition particle (SRP) antibodies: A case report. [abstract]. *International Journal of Gynecology and Obstetrics* 2012;119(Suppl\_3):S770.
23. de Boer, NK, Jarbandhan, SV, de Graaf, P, *et al.* Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. *Am J Gastroenterol* 2006;101:1390-2.
24. Ferrau, F, Gangemi, S, Vita, G, *et al.* Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. *Fertil Steril* 2011;95:2430.e15-7.
25. Koukoura, O, Mantas, N, Linardakis, H, *et al.* Successful term pregnancy in a patient with Wegener's granulomatosis: case report and literature review. *Fertil Steril* 2008;89:457 e1-5.
26. Lehman, JS, Mueller, KK, Schraith, DF. Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy? *Arch Dermatol* 2008;144:783-5.
27. Silva, F, Specks, U, Sethi, S, *et al.* Successful Pregnancy and Delivery of a Healthy Newborn Despite Transplacental Transfer of Antimyeloperoxidase Antibodies From a Mother With Microscopic Polyangiitis. *Am J Kidney Dis* 2009;54:542-45.
28. Tuin, J, Sanders, JS, de Joode, AA, *et al.* Pregnancy in women diagnosed with antineutrophil cytoplasmic antibody-associated vasculitis: outcome for the mother and the child. *Arthritis Care Res (Hoboken)* 2012;64:539-45.
29. Angelucci, E, Cesarini, M, Vernia, P. Inadvertent conception during concomitant treatment with infliximab and methotrexate in a patient with Crohn's disease: Is the game worth the candle? *Inflamm Bowel Dis* 2010;16:1641-42.

30. Corona-Rivera, JR, Rea-Rosas, A, Santana-Ramirez, A, *et al.* Holoprosencephaly and genitourinary anomalies in fetal methotrexate syndrome. *American Journal of Medical Genetics, Part A* 2010;152:1741-46.
31. Georgiou, EX, Domoney, C, Savage, P, *et al.* Heterotopic abdominal pregnancy with persistent trophoblastic tissue. *Acta Obstet Gynecol Scand* 2011;90:551-3.
32. Mulholland, CP, Pollock, TJ. The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine. *Can J Ophthalmol* 2011;46:289-90.
33. Neeman, N, Aronson, MD, Schulze, JE, *et al.* Improving pregnancy counseling for women with rheumatoid arthritis taking methotrexate. *Am J Med* 2009;122:998-1000.
34. Piggott, KD, Sorbello, A, Riddle, E, *et al.* Congenital cardiac defects: a possible association of aminopterin syndrome and in utero methotrexate exposure? *Pediatr Cardiol* 2011;32:518-20.
35. Poggi, SH, Ghidini, A. Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy. *Fertil Steril* 2011;96:669-71.
36. Singh, Y, Shankar, A. Fetal anomalies in rheumatoid arthritis patient exposed to low dose methotrexate. *Medical Journal Armed Forces India* 2009;65:80-81.
37. Adam, FU, Torun, D, Bolat, F, *et al.* Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjogren's syndrome. *Clin Rheumatol* 2006;25:75-9.
38. Ali, R, Ozkalemkas, F, Kimya, Y, *et al.* Acute leukemia and pregnancy. *Leuk Res* 2009;33:e26-8.
39. Ataergin, S, Kanat, O, Arpaci, F, *et al.* A rare occurrence of diffuse lymphoblastic lymphoma in pregnancy. *Am J Hematol* 2007;82:173-4.
40. Ateser, G, Yildiz, O, Leblebici, C, *et al.* Metastatic primitive neuroectodermal tumor of the ovary in pregnancy. *Int J Gynecol Cancer* 2007;17:266-9.
41. Bodner-Adler, B, Bodner, K, Zeisler, H. Breast cancer diagnosed during pregnancy. *Anticancer Res* 2007;27:1705-7.
42. Brudie, LA, Ahmad, S, Radi, MJ, *et al.* Metastatic choriocarcinoma in a viable intrauterine pregnancy treated with EMA-CO in the third trimester: a case report. *J Reprod Med* 2011;56:359-63.
43. Cordeiro, A, Machado, AI, Borges, A, *et al.* Burkitt's lymphoma related to Epstein-Barr virus infection during pregnancy. *Arch Gynecol Obstet* 2009;280:297-300.
44. Cordoba, O, Llubra, E, Cortes, J, *et al.* Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy. *Tumori* 2010;96:629-32.
45. Diamond, JR, Finlayson, CA, Thienelt, C, *et al.* Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. *Oncology (Williston Park)* 2009;23:784-91.
46. Escobar, MR. Successful pregnancy after inadvertent exposure to cyclophosphamide in the first trimester in a patient with active lupus. case report. *Iatreia* 2011;24:320-24.
47. Fernandez, M, Andrade, R, Alarcon, GS. Cyclophosphamide use and pregnancy in lupus. *Lupus* 2006;15:59.
48. Garcia-Manero, M, Royo, MP, Espinos, J, *et al.* Pregnancy associated breast cancer. *Eur J Surg Oncol* 2009;35:215-8.
49. Gupta, R, Deepanjali, S, Thabab, MM, *et al.* Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis. *Rheumatol Int* 2009;29:1503-5.
50. Lam, MS. Treatment of Burkitt's lymphoma during pregnancy. *Ann Pharmacother* 2006;40:2048-52.
51. Lannes, G, Elias, FR, Cunha, B, *et al.* Successful pregnancy after cyclophosphamide therapy for lupus nephritis. *Arch Gynecol Obstet* 2011;283 Suppl 1:61-5.
52. Lazalde, B, Grijalva-Flores, J, Guerrero-Romero, F. Klippel-Feil syndrome in a boy exposed inadvertently to cyclophosphamide during pregnancy: a case report. *Birth Defects Research* 2012;94:249-52.

53. Lee, EJ, Ahn, KH, Hong, SC, *et al.* Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth. *Obstet Gynecol Sci* 2014;57:526-9.
54. Leyder, M, Laubach, M, Breugelmans, M, *et al.* Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy. *Gynecol Obstet Invest* 2011;71:141-4.
55. Logue, K. Pregnancy-associated breast cancer. *Clin J Oncol Nurs* 2009;13:25-7.
56. Morris, PG, King, F, Kennedy, MJ. Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case series. *J Oncol Pharm Pract* 2009;15:241-7.
57. Parks, LP, Thomas, A, Johnson, D. Treating Lupus Nephritis with Cyclophosphamide during Pregnancy. [abstract]. *J Investig Med* 2012;60(1):332.
58. Perez, CA, Amin, J, Aguina, LM, *et al.* Primary Mediastinal Large B-Cell Lymphoma during Pregnancy. *Case Rep Hematol* 2012;2012:197347.
59. Pirvulescu, C, Mau, C, Schultz, H, *et al.* Breast Cancer during Pregnancy: An Interdisciplinary Approach in Our Institution. *Breast Care (Basel)* 2012;7:311-4.
60. Rey, J, Coso, D, Roger, V, *et al.* Rituximab combined with chemotherapy for lymphoma during pregnancy. *Leuk Res* 2009;33:e8-9.
61. Selig, BP, Furr, JR, Huey, RW, *et al.* Cancer chemotherapeutic agents as human teratogens. *Birth Defects Res A Clin Mol Teratol* 2012;94:626-50.
62. Shalaby, MA, Habeeb, SM, Mohamed, FM. Cyclophosphamide therapy in pregnant SLE, does not necessitate termination of pregnancy: Case report. [abstract]. *Lupus* 2010;19(Suppl):181-2.
63. Sharma, JB, Pushparaj, M, Kumar, S, *et al.* Successful pregnancy outcome with 5-fluorouracil, epirubicin, cyclophosphamide chemotherapy, and hemostatic radiotherapy with abdominal shielding for metastatic invasive intraductal breast carcinoma. *Arch Gynecol Obstet* 2009;279:415-7.
64. Smyth, EC, Korpany, G, McCaffrey, JA, *et al.* Small-cell carcinoma of the cervix at 23 weeks gestation. *J Clin Oncol* 2010;28:e295-7.
65. Agapidou, A, Vlachaki, E, Theodoridis, T, *et al.* Cyclosporine therapy during pregnancy in a patient with beta-thalassemia major and autoimmune haemolytic anemia: a case report and review of the literature. *Hippokratia* 2013;17:85-7.
66. Coscia, LA, Constantinescu, S, Moritz, MJ, *et al.* Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. *Clin Transpl* 2009:103-22.
67. Ghafari, A, Sanadgol, H. Pregnancy after renal transplantation: ten-year single-center experience. *Transplant Proc* 2008;40:251-2.
68. Hazarika, D. Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine. *Indian J Dermatol Venereol Leprol* 2009;75:638.
69. Jabiry-Zieniewicz, Z, Szpotanska-Sikorska, M, Pietrzak, B, *et al.* Pregnancy outcomes among female recipients after liver transplantation: further experience. *Transplant Proc* 2011;43:3043-7.
70. Kashif, W, Yaqub, S, Ahmed, H, *et al.* Successful pregnancy in a kidney transplant recipient with chronic hepatitis B virus infection. *Iran J Kidney Dis* 2013;7:407-11.
71. Mazzuocolo, LD, Andrada, R, Pellerano, G, *et al.* Levels of cyclosporine in breast milk and passage into the circulation of the infant of a mother with psoriasis. *Int J Dermatol* 2014;53:355-56.
72. Rocha, A, Cardoso, A, Malheiro, J, *et al.* Pregnancy after kidney transplantation: graft, mother, and newborn complications. *Transplant Proc* 2013;45:1088-91.
73. Shimizu, M, Sakakibara, Y, Kawano, M, *et al.* Transient impairment of NK cell function in an infant born to a mother with adult-onset Still's disease: perinatal effect of maternal IL-18. *Clin Immunol* 2012;143:273-4.

74. Wen, YF, Zuo, XX. Successful pregnancy and delivery in a patient with systemic lupus erythematosus treated with cyclosporin: A case report and a review of the literature. [abstract]. *Int J Rheum Dis* 2010;13(Suppl\_1):244.
75. Bramham, K, Nelson-Piercy, C, Gao, H, et al. Pregnancy in renal transplant recipients: a UK national cohort study. *Clin J Am Soc Nephrol* 2013;8:290-8.
76. Costa, ML, Surita, FG, Passini, R, Jr., et al. Pregnancy outcome in female liver transplant recipients. *Transplant Proc* 2011;43:1337-9.
77. Ducarme, G, Theron-Gerard, L, Duvoux, C, et al. Pregnancy after liver transplantation with tacrolimus. *Eur J Obstet Gynecol Reprod Biol* 2007;133:249-50.
78. Ecevit, C, Unal, F, Baran, M, et al. Parenthood in pediatric liver transplant patients. *Pediatr Transplant* 2012;16:346-9.
79. Gomez-Lobo, V, Landy, HJ, Matsumoto, C, et al. Pregnancy in an intestinal transplant recipient. *Obstet Gynecol* 2012;120:497-500.
80. Izumi, Y, Miyashita, T, Migita, K. Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: A report of two patients. *Tohoku J Exp Med* 2014;234:51-56.
81. Webster, P, Wardle, A, Bramham, K, et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. *Lupus* 2014;23:1192-6.
82. Zheng, S, Easterling, TR, Hays, K, et al. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. *Br J Clin Pharmacol* 2013;76:988-96.
83. Anderka, MT, Lin, AE, Abuelo, DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. *Am J Med Genet A* 2009;149a:1241-8.
84. Andrade Vila, JH, da Silva, JP, Guilhen, CJ, et al. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. *Transplantation* 2008;86:369-70.
85. Ang, GS, Simpson, SA, Reddy, AR. Mycophenolate mofetil embryopathy may be dose and timing dependent. *Am J Med Genet A* 2008;146a:1963-6.
86. Dei Malatesta, MF, Rocca, B, Gentile, T, et al. A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation. [abstract]. *Transplant Proc* 2009;41(4):1407-9.
87. El Sebaaly, Z, Charpentier, B, Snanoudj, R. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. *Nephrol Dial Transplant* 2007;22:2722.
88. Huang, SY, Chueh, HY, Shaw, SW, et al. Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. *Am J Obstet Gynecol* 2008;199:e6-e8.
89. Jackson, P, Paquette, L, Watiker, V, et al. Intrauterine exposure to mycophenolate mofetil and multiple congenital anomalies in a newborn: possible teratogenic effect. *Am J Med Genet A* 2009;149a:1231-6.
90. Klieger-Grossmann, C, Chitayat, D, Lavign, S, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. *J Obstet Gynaecol Can* 2010;32:794-7.
91. Koshy, AN, Strong, D, Earles, G, et al. Congenital malformations with low-dose mycophenolate mofetil after kidney transplantation. *Nephrology* 2010;15:133-35.
92. Lin, AE, Singh, KE, Strauss, A, et al. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. *Am J Med Genet A* 2011;155a:748-56.
93. Martin, MC, Cristiano, E, Villanueva, M, et al. Esophageal atresia and prenatal exposure to mycophenolate. *Reprod Toxicol* 2014;50:117-21.
94. Ortiz, EC, Torralba, KD, Evelyn, CM, et al. Fetal and maternal outcomes with mycophenolate mofetil (MMF) exposure during first trimester of pregnancy in patients with systemic lupus erythematosus. [abstract]. *Arthritis Rheum* 2009;60(Suppl 10):1587.
95. Parisi, MA, Zayed, H, Slavotinek, AM, et al. Congenital diaphragmatic hernia and microtia in a newborn with mycophenolate mofetil (MMF) exposure: phenocopy for Fryns syndrome or broad spectrum of teratogenic effects? *Am J Med Genet A* 2009;149A:1237-40.

96. Perez-Aytes, A, Ledo, A, Boso, V, *et al.* In utero exposure to mycophenolate mofetil: a characteristic phenotype? *Am J Med Genet A* 2008;146a:1-7.
97. Ruiz-campillo, C, Castillo, F, Perapoch, J, *et al.* Mycophenolate Mofetil Use for Lupus Nephritis During Pregnancy: Report Of a Case Of Fetal Malformations And Literature Update. *The Internet Journal of Gynecology and Obstetrics* 2008;11.
98. Schoner, K, Steinhard, J, Figiel, J, *et al.* Severe facial clefts in acrofacial dysostosis: A consequence of prenatal exposure to mycophenolate mofetil? *Obstet Gynecol* 2008;111:483-86.
99. Tayebi, Z, Taqhavi, SA, Shahbazi, S. Successful Pregnancies in Two Orthotopic Liver Transplant (OLT) Recipients in Iran; Two Case Reports. *Journal of Reproduction & Infertility* 2009;10:225.
100. Tjeertes, IF, Bastiaans, DE, van Ganzewinkel, CJ, *et al.* Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. *J Perinatol* 2007;27:62-4.
101. Velinov, M, Zellers, N. The fetal mycophenolate mofetil syndrome. *Clin Dysmorphol* 2008;17:77-8.
102. Noel, N, Wechsler, B, Nizard, J, *et al.* Behcet's disease and pregnancy. *Arthritis Rheum* 2013;65:2450-6.
103. Linardaki, G, Cherouvim, E, Goni, G, *et al.* Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis. *Rheumatol Int* 2011;31:113-5.
104. Stojanovich, L, Mikovic, Z, Mandic, V, *et al.* Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin. *Isr Med Assoc J* 2007;9:555-56.
105. Williams, L, Chang, PY, Park, E, *et al.* Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. *Obstet Gynecol* 2007;109:561-3.
106. Marren, A, Chen, Y, Frazier, D, *et al.* Pregnancy outcomes in the tofacitinib RA safety database through april 2014. [abstract]. *Arthritis and Rheumatology* 2014;66(Suppl S10):S840.
107. Akinci, A, Ozcakar, L. Infliximab use during pregnancy revisited. *Acta Reumatol Port* 2008;33:374-5.
108. Angelucci, E, Cocco, A, Viscido, A, *et al.* Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. *Inflamm Bowel Dis* 2008;14:435-36.
109. Aratari, A, Margagnoni, G, Koch, M, *et al.* Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. *Journal of Crohn's & colitis* 2011;5:262.
110. Arguelles-Arias, F, Castro-Laria, L, Barreiro-de Acosta, M, *et al.* Is safety infliximab during pregnancy in patients with inflammatory bowel disease? *Rev Esp Enferm Dig* 2012;104:59-64.
111. Berthelot, JM, De Bandt, M, Goupille, P, *et al.* Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. *Joint Bone Spine* 2009;76:28-34.
112. Chaparro, M, Gisbert, JP. Successful use of infliximab for perianal Crohn's disease in pregnancy. *Inflamm Bowel Dis* 2011;17:868-69.
113. Cheent, K, Nolan, J, Shariq, S, *et al.* Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease. *Journal of Crohn's and Colitis* 2010;4:603-05.
114. Correia, LM, Bonilha, DQ, Ramos, JD, *et al.* Inflammatory bowel disease and pregnancy: Report of two cases treated with infliximab and a review of the literature. *Eur J Gastroenterol Hepatol* 2010;22:1260-64.
115. Epping, G, van der Valk, PD, Hendrix, R. Legionella pneumophila pneumonia in a pregnant woman treated with anti-TNF-alpha antibodies for Crohn's disease: a case report. *J Crohns Colitis* 2010;4:687-9.
116. Hou, JK, Mahadevan, U. A 24-Year-Old Pregnant Woman With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol* 2009;7:944-47.
117. Ishikawa, H, Hirano, Y, Kaneko, A, *et al.* Pregnancy in patients with rheumatoid arthritis treated with biological agents: Results of the 8-year of japanese tbc registry. [abstract]. *Annals of the Rheumatic Disease* 2013;71(Suppl\_3):501.
118. Jarosova, K, Hejduk, K, Uher, M, *et al.* Pregnancy outcome in adult juvenile idiopathic arthritis patients treated with biologic agents. [abstract]. *Ann Rheum Dis* 2014;73(Suppl\_2):583.

119. Kane, S, Ford, J, Cohen, R, *et al.* Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. *J Clin Gastroenterol* 2009;43:613-6.
120. Mainini, G, Di Donna, MC, Esposito, E, *et al.* Pregnancy management in Behcet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature. *Clin Exp Obstet Gynecol* 2014;41:205-7.
121. Slama, W, Roc, E, Carlier, P, *et al.* Pregnancy outcome in women exposed to anti tumor necrosis factor therapy. [abstract]. *Fundam Clin Pharmacol* 2010;24(Suppl):89.
122. Snoeckx, Y, Clark, M, Geldhof, A, *et al.* Pregnancy outcomes in women with inflammatory bowel disease exposed to infliximab. [abstract]. *Journal of Crohn's and Colitis* 2013;7(Suppl):S170.
123. Steenholdt, C, Al-Khalaf, M, Ainsworth, MA, *et al.* Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. *Journal of Crohn's and Colitis* 2012;6:358-61.
124. Dessinioti, C, Stefanaki, I, Stratigos, AJ, *et al.* Pregnancy during adalimumab use for psoriasis. *J Eur Acad Dermatol Venereol* 2011;25:738-9.
125. Julsgaard, M, Brown, S, Gibson, P, *et al.* Adalimumab levels in an infant. *J Crohns Colitis* 2013;7:597-8.
126. Jurgens, M, Brand, S, Filik, L, *et al.* Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. *Inflamm Bowel Dis* 2010;16:1634-6.
127. Mizoshita, T, Tanida, S, Tsukamoto, H, *et al.* Maintenance of the remission stage of Crohn's disease with adalimumab therapy during pregnancy. *Intern Med* 2013;52:1049-53.
128. Furukawa, K, Maeshima, E, Ichinose, M. A case of successful pregnancy and childbirth in a rheumatoid arthritis patient treated with etanercept. *Japanese Journal of Clinical Immunology* 2013;36:47-51.
129. Hemmati, I, Ensworth, S, Shojanian, K. Coarctation of the aorta in an infant exposed to etanercept in utero. *J Rheumatol* 2009;36:2848.
130. Murashima, A, Watanabe, N, Ozawa, N, *et al.* Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: Drug levels in maternal serum, cord blood, breast milk and the infant's serum. *Ann Rheum Dis* 2009;68:1793-94.
131. Natsumi, I, Matsukawa, Y, Miyagawa, K, *et al.* Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. *Rheumatol Int* 2013;33:2433-35.
132. Rump, JA, Schonborn, H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. *Z Rheumatol* 2010;69:903-9.
133. Scioscia, C, Scioscia, M, Anelli, MG, *et al.* Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis. *Clin Exp Rheumatol* 2011;29:93-5.
134. Tsuchida, T. Follow-up investigation of efficacy/safety of etanercept in patients who successfully became pregnant after its introduction. [abstract]. *Ann Rheum Dis* 2014;73(Suppl\_2):484.
135. Umeda, N, Ito, S, Hayashi, T, *et al.* A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. *Intern Med* 2010;49:187-89.
136. Clowse, ME, Wolf, DC, Forger, F, *et al.* Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. *J Rheumatol* 2015;42:2270-8.
137. Oussalah, A, Bigard, MA, Peyrin-Biroulet, L. Certolizumab use in pregnancy. *Gut* 2009;58:608.
138. Lau, A, Clark, M, Harrison, DD, *et al.* Pregnancy outcomes in women exposed to the tumor necrosis factor inhibitor, Golimumab. [abstract]. *Ann Rheum Dis* 2014;73(Suppl\_2):232-3.
139. Clowse, ME, Förger, F, Cush, J, *et al.* Pregnancy Outcomes with Trimesters of Maternal Exposure to Certolizumab Pegol: Prospective and Retrospective Reports from Safety Surveillance. [abstract]. *Ann Rheum Dis* 2015;74(Suppl 2):71.
140. Burnette, BL, Jentoft, MA, Porrata, LF, *et al.* Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management. *J Clin Oncol* 2014;32:e14-7.
141. Chakravarty, EF, Murray, ER, Kelman, A, *et al.* Pregnancy outcomes after maternal exposure to rituximab. *Blood* 2011;117:1499-506.



142. Daver, N, Nazha, A, Kantarjian, HM, *et al.* Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. *Clin Lymphoma Myeloma Leuk* 2013;13:86-9.
143. Decker, M, Rothermundt, C, Hollander, G, *et al.* Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. *Lancet Oncol* 2006;7:693-4.
144. Friedrichs, B, Tiemann, M, Salwender, H, *et al.* The effects of rituximab treatment during pregnancy on a neonate. *Haematologica* 2006;91:1426-7.
145. Gall, B, Yee, A, Berry, B, *et al.* Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. *J Obstet Gynaecol Can* 2010;32:1167-71.
146. Gualtierotti, R, Ingegnoli, F, Meroni, PL. Pre-conceptional exposure to rituximab: Comment on the article by Ojeda-Urbe *et al.* *Clin Rheumatol* 2013;32:727-28.
147. Klink, DT, van Elburg, RM, Schreurs, MW, *et al.* Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. *Clin Dev Immunol* 2008;2008:271363.
148. Magloire, LK, Pettker, CM, Buhimschi, CS, *et al.* Burkitt's lymphoma of the ovary in pregnancy. *Obstet Gynecol* 2006;108:743-5.
149. Martinez-Martinez, MU, Baranda-Candido, L, Gonzalez-Amaro, R, *et al.* Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. *Rheumatology (Oxford)* 2013;52:405-6.
150. Ojeda-Urbe, M, Afif, N, Dahan, E, *et al.* Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. *Clin Rheumatol* 2013;32:695-700.
151. Ojeda-Urbe, M, Gilliot, C, Jung, G, *et al.* Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. *J Perinatol* 2006;26:252-5.
152. Pellkofer, HL, Suessmair, C, Schulze, A, *et al.* Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. *Mult Scler* 2009;15:1006-8.
153. Pendergraft, WF, 3rd, McGrath, MM, Murphy, AP, *et al.* Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. *Ann Rheum Dis* 2013;72:2051-3.
154. Ponte, P, Lopes, MJ. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. *J Am Acad Dermatol* 2010;63:355-6.
155. Ringelstein, M, Harmel, J, Distelmaier, F, *et al.* Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. *Mult Scler* 2013;19:1544-7.
156. Sangle, SR, Lutalo, PM, Davies, RJ, *et al.* B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. *J Autoimmun* 2013;43:55-9.
157. Scully, M, Starke, R, Lee, R, *et al.* Successful management of pregnancy in women with a history of thrombotic thrombocytopenic purpura. *Blood Coagul Fibrinolysis* 2006;17:459-63.
158. Ton, E, Tekstra, J, Hellmann, PM, *et al.* Safety of rituximab therapy during twins' pregnancy. *Rheumatology (Oxford)* 2011;50:806-8.
159. Berger, CT, Recher, M, Steiner, U, *et al.* A patient's wish: Anakinra in pregnancy. *Ann Rheum Dis* 2009;68:1794-95.
160. Chang, Z, Spong, C, Jesus, AA, *et al.* Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). *Arthritis Rheumatol* 2014;66:3227-32.
161. Fischer-Betz, R, Specker, C, Schneide, M. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra). *Clin Exp Rheumatol* 2011;29:1021-23.
162. Kumar, M, Ray, L, Vemuri, S, *et al.* Pregnancy outcomes following exposure to abatacept during pregnancy. *Semin Arthritis Rheum* 2015;45:31-31.
163. Ishikawa, H, Kaneko, A, Hattori, Y, *et al.* Pregnancy outcomes in rheumatoid arthritis patients treated with tocilizumab. [abstract]. *Ann Rheum Dis* 2014;73(Suppl\_2):501-2.
164. Rubbert-Roth, A, Goupille, PM, Moosavi, S, *et al.* First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy. [abstract]. *Arthritis Rheum* 2010;62(Suppl S10):384.

165. Andrulonis, R, Ferris, LK. Treatment of severe psoriasis with ustekinumab during pregnancy. *Journal of Drugs in Dermatology* 2012;11:1240-41.
166. Fotiadou, C, Lazaridou, E, Sotiriou, E, *et al.* Spontaneous abortion during ustekinumab therapy. *J Dermatol Case Rep* 2012;6:105-7.
167. Schaufelberg, BW, Horn, E, Cather, JC, *et al.* Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program. [abstract]. *J Am Acad Dermatol* 2014;1(Suppl 5):AB178.
168. Sheeran, C, Nicolopoulos, J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. *Australas J Dermatol* 2014;55:235-36.
169. Powell, M, Hill, D, Eudy, A. Pregnancy outcomes for systemic lupus erythematosus (SLE) subjects with conception during Belimumab intravenous (iv) and subcutaneous (sc) placebo-controlled clinical trials and long term extension trials. [abstract]. *Ann Rheum Dis* 2014;73(Suppl 2):75-76.